Blood Cancer Treatment Market By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, and Others), By End-user (Hospitals, Clinics, Cancer Rehabilitation Centers, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Blood Cancer Treatment Market size is expected to be worth around US$ 15.7 Billion by 2033, from US$ 5.9 Billion in 2023, growing at a CAGR of 10.3% during the forecast period from 2024 to 2033.

Rising prevalence of blood cancers and the growing demand for more effective therapies are driving the expansion of the blood cancer treatment market. Blood cancers, including leukemia, lymphoma, and myeloma, require specialized treatments that target the unique characteristics of cancerous blood cells.

Recent advancements in targeted therapies and immunotherapies have significantly improved patient outcomes and expanded treatment options. In April 2021, the US Food and Drug Administration (FDA) approved BCMA-targeted CAR T-Cell Therapy for blood cancers, a groundbreaking development based on research demonstrating that idecabtagene vicleucel (ide-cel) reduced tumor size in 72% of patients, with effects lasting on average for 11 months.

This approval highlights the growing shift toward personalized and precision medicine in oncology. Furthermore, in June 2021, Bayer submitted a supplemental new drug application (sNDA) to the FDA and a marketing authorization application (MAA) to the European Medicines Agency (EMA) for a combination of copanlisib and rituximab to treat oncology patients. These efforts reflect the increasing importance of combination therapies in treating complex blood cancers.

Rising investments in biotechnology and ongoing research into innovative drug delivery systems, such as antibody-drug conjugates, provide substantial opportunities for market growth. Additionally, the development of next-generation CAR T-cell therapies and bispecific antibodies presents new avenues for targeting previously difficult-to-treat cancers. With expanding pipelines and breakthroughs in immuno-oncology, the blood cancer treatment market is poised for continued growth, offering new hope for patients and healthcare providers alike.

Key Takeaways

• In 2023, the market for blood cancer treatment generated a revenue of US$ 5.9 billion, with a CAGR of 10.3%, and is expected to reach US$ 15.7 billion by the year 2033.
• The treatment type segment is divided into chemotherapy, radiation therapy, targeted therapy, and others, with chemotherapy taking the lead in 2023 with a market share of 42.8%.
• Considering end-user, the market is divided into hospitals, clinics, cancer rehabilitation centers, and others. Among these, hospitals held a significant share of 49.7%.
• North America led the market by securing a market share of 42.1% in 2023.

Treatment Type Analysis

The chemotherapy segment led in 2023, claiming a market share of 42.8% owing to its established role as one of the most common and effective treatments for various types of blood cancers, including leukemia, lymphoma, and myeloma. Chemotherapy remains a cornerstone in the treatment of aggressive cancers, as it targets rapidly dividing cancer cells.

The increasing prevalence of blood cancers and the continuous advancements in chemotherapy regimens, such as combination therapies, are anticipated to contribute to the segment’s growth. Additionally, the introduction of chemotherapy agents with improved efficacy and fewer side effects is projected to drive market demand. As new chemotherapeutic drugs are developed to treat blood cancers more effectively, this segment is likely to continue its expansion, particularly in regions with high cancer rates.

End-user Analysis

The hospitals held a significant share of 49.7% due to the central role that hospitals play in diagnosing and treating blood cancer patients. Hospitals are expected to remain the primary setting for administering blood cancer treatments, as they provide access to a wide range of specialized services, including chemotherapy, radiation therapy, and stem cell transplants.

The rising demand for advanced blood cancer treatments, particularly those involving multi-disciplinary care, is anticipated to drive growth in this segment. Additionally, the increasing number of cancer cases globally, along with advancements in personalized medicine and targeted therapies, is expected to further support the demand for hospital-based treatments. Hospitals’ investment in cutting-edge technology and specialized oncology departments will likely enhance their ability to treat blood cancers, contributing to the continued expansion of this segment in the market.

Key Market Segments

By Treatment Type

• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Others

By End-user

• Hospitals
• Clinics
• Cancer Rehabilitation Centers
• Others

Drivers

Growing Prevalence of Blood Cancer Driving the Market

The growing prevalence of blood cancer is significantly driving the blood cancer treatment market. According to a survey by Bristol-Myers Squibb, it is estimated that by 2040, approximately 1.85 million new cases of blood cancer will be diagnosed worldwide. This includes 918,872 cases of lymphoma, 656,345 cases of leukemia, and 275,047 cases of myeloma. The increasing number of cases underscores the rising demand for effective treatments and therapies.

As blood cancer diagnoses continue to rise, healthcare systems worldwide are expected to focus more on developing and distributing targeted therapies. The need for effective treatments is anticipated to intensify, making the market for blood cancer therapies crucial in the coming years.

The prevalence of various types of blood cancers, especially among older populations, is projected to further accelerate demand for specialized treatment options. As awareness and research into blood cancers grow, new treatment modalities are likely to be developed, fostering market expansion.

Restraints

High Treatment Costs Restraining the Market

High treatment costs are expected to restrain the growth of the blood cancer treatment market. The costs associated with blood cancer treatments, including chemotherapy, immunotherapy, and stem cell transplants, are rising due to the complexity and duration of treatment regimens. These high costs are anticipated to impede access to life-saving therapies, especially in low- and middle-income countries where healthcare systems are less equipped to cover the expenses.

For patients without adequate insurance or financial resources, the burden of treatment costs could lead to delays in starting necessary therapies or opting for less effective alternatives. The financial strain on healthcare systems is expected to hinder the widespread adoption of the latest blood cancer therapies, despite their proven effectiveness.

Additionally, long-term care requirements and frequent follow-ups only add to the financial challenges, limiting the ability of many to fully benefit from the advances in blood cancer treatment. The high cost of treatment is likely to continue as a significant barrier to optimal care, affecting market growth.

Opportunities

Increase in R&D Activities Creating Opportunities in the Market

The increase in research and development (R&D) activities presents a significant opportunity for the blood cancer treatment market. Growing investments in R&D by pharmaceutical companies and academic institutions are accelerating the discovery of novel therapies and innovative treatment options for blood cancer. In November 2023, Roswell Park Comprehensive Cancer Center introduced PanHeme, a next-generation sequencing (NGS) technology capable of identifying mutations in hundreds of genes in under 72 hours.

This technology shortens the previous wait time from 3 to 4 weeks, allowing for faster, more accurate diagnosis and treatment planning. The development of such advanced diagnostic tools is expected to enhance treatment precision, improving patient outcomes. With increasing research into targeted therapies, immunotherapies, and personalized medicine, the market is likely to see a surge in new treatment options.

The focus on discovering more effective and less toxic treatments will drive market growth, as more patients are likely to gain access to therapies tailored to their specific genetic profiles. The increasing number of collaborations between research institutions and pharmaceutical companies will further accelerate innovation in blood cancer treatments.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors significantly affect the blood cancer treatment market, influencing both research and patient access to therapies. Economic recessions can lead to reduced healthcare budgets, potentially slowing the development of new treatments and limiting patient access to innovative therapies.

On the other hand, periods of economic growth often increase healthcare spending, which can boost investment in the development of advanced blood cancer treatments. Geopolitical factors, such as regulatory changes, international trade policies, and political instability, can disrupt the global supply chain, leading to delays in drug manufacturing or distribution. Additionally, currency fluctuations may impact the cost of treatments in different regions.

However, the rising global prevalence of blood cancers, along with advancements in immunotherapy and precision medicine, continues to create a strong demand for new therapeutic options. With increasing support for cancer research, the market for blood cancer therapies is expected to continue growing, offering improved treatment outcomes for patients worldwide.

Trends

Rising Clinical Trials Driving the Blood Cancer Treatment Market

Rising clinical trials are driving significant growth in the blood cancer treatment market. Increased investment in clinical research is fast-tracking the development of new therapies, offering fresh treatment options for patients. The surge in clinical trials underscores a deepening commitment to overcoming the challenges of hematologic malignancies.

In January 2024, Merck launched Phase 3 trials for four investigational treatments aimed at both hematologic malignancies and solid tumors. Among these, the BELLWAVE-011 clinical trial (NCT06136559) is notable. It evaluates nemtabrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor, targeting chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The trial seeks to broaden therapeutic choices for blood cancer patients, highlighting a strong focus on enhancing treatment efficacy. With ongoing expansions in clinical trials, the market for blood cancer treatments is poised for considerable growth. This progression is expected to usher in more innovative therapies in the upcoming years.

Regional Analysis

North America is leading the Blood Cancer Treatment Market

North America dominated the market with the highest revenue share of 42.1% owing to advances in targeted therapies, immunotherapies, and increasing healthcare investment. The growing incidence of blood cancers such as leukemia, lymphoma, and myeloma has driven demand for innovative treatments. According to the Leukemia and Lymphoma Society, approximately 59,610 new cases of leukemia were expected to be diagnosed in the US in 2023, with an estimated 437,337 people currently living with or in remission from leukemia.

This increasing patient population, combined with advancements in precision medicine, has led to an expanding market for blood cancer treatments. The growing popularity of CAR-T cell therapies, monoclonal antibodies, and kinase inhibitors has revolutionized treatment options, improving patient outcomes and survival rates.

Additionally, the increasing number of clinical trials focused on blood cancer therapies has accelerated the development of new treatment options, further boosting the market. The availability of personalized treatment regimens and advancements in combination therapies are also expected to continue driving market growth in North America.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow with the fastest CAGR owing to the rising prevalence of blood cancers, improving healthcare infrastructure, and increasing access to advanced therapies. As the region’s population continues to age, the incidence of blood cancers is anticipated to rise, contributing to greater demand for treatment options.

The adoption of immunotherapies and targeted therapies, which have shown promising results in clinical settings, is likely to increase, offering patients more effective treatment options. In particular, countries like China and India are expected to see significant growth in blood cancer diagnoses, which will drive demand for novel treatments.

Additionally, the expansion of healthcare systems in emerging economies, alongside increased awareness of cancer treatments, is projected to play a crucial role in market development. The increasing number of multinational pharmaceutical companies entering the region, coupled with government initiatives to improve access to cancer care, will likely contribute to the overall growth of the blood cancer treatment market in Asia Pacific.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major players in the blood cancer treatment market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the blood cancer treatment market adopt strategies such as focusing on targeted therapies, expanding immuno-oncology pipelines, and enhancing global access to treatments.

Companies prioritize the development of novel therapies, including CAR T-cell therapies and checkpoint inhibitors, to improve patient outcomes. Collaboration with research institutions accelerates the discovery of innovative treatment options. Additionally, companies increase their presence in emerging markets through strategic partnerships and by obtaining regulatory approvals. Investment in personalized medicine and expanding clinical trial programs further supports the growth of novel blood cancer treatments.

One of the key players in the market is Bristol-Myers Squibb, a global biopharmaceutical company that specializes in immuno-oncology and hematology therapies. Bristol-Myers Squibb’s portfolio includes leading treatments for blood cancers, including leukemia and lymphoma.

The company’s growth strategy centers on advancing its oncology pipeline, expanding its market share through acquisitions, and leveraging its expertise in immune system modulation to develop cutting-edge therapies. Bristol-Myers Squibb also partners with healthcare providers and academic researchers to advance clinical development and bring innovative therapies to patients globally.

Top Key Players in the Blood Cancer Treatment Market

• SkylineDx
• Quest Diagnostics
• Ipsogen
• InVivoScribe
• Illumina
• Danaher Corporation
• BD
• Asuragen
• Alercell, Inc
• Abbott

 Recent Developments

• In April 2023: Alercell, Inc. launched the LENA Molecular Dx Leukemia Platform, a suite of 12 molecular diagnostic tests for early leukemia detection, treatment guidance, and monitoring minimal residual disease. The platform uses next-generation DNA sequencing technology to enhance diagnostic precision.
• In February 2022: BD acquired Cytognos, a private company specializing in flow cytometry solutions for diagnosing blood cancers, detecting minimal residual disease, and conducting immune monitoring research, further strengthening BD’s presence in the blood cancer diagnostics market.

Report Scope